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Alzheimer’s disease (AD) is the most prevalent, severe, and disabling cause of dementia worldwide.
To date, AD therapy is primarily targeted toward palliative treatment of symptoms rather than
prevention of disease progression. So far, no pharmacologic interventions have changed the onset
or progression of AD and their use is accompanied by side effects. The major obstacle in managing
AD and designing therapeutic strategies is the difﬁculty in retarding neuronal loss in the diseased
brain once the pathologic events leading to neuronal death have started. Therefore, a promising
alternative strategy is to maintain a healthy neuronal population in the aging brain for as long as
possible. One factor evidently important for neuronal health and function is the optimal supply of
nutrients necessary for maintaining normal functioning of the brain. Mechanistic studies, epide-
miologic analyses, and randomized controlled intervention trials provide insight to the positive
effects of docosahexaenoic acid (DHA) and micronutrients such as the vitamin B family, and vi-
tamins E, C, and D, in helping neurons to cope with aging. These nutrients are inexpensive in use,
have virtually no side effects when used at recommended doses, are essential for life, have
established modes of action, and are broadly accepted by the general public. This review provides
some evidence that the use of vitamins and DHA for the aging population in general, and for in-
dividuals at risk in particular, is a viable alternative approach to delaying brain aging and for
protecting against the onset of AD pathology.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
In the 20th century, life expectancy increased by > 30 y,
which, combined with declining fertility rates, led to a dramatic
shift in demographic characteristics [1]. By the year 2040, more
than one in four Europeans will be older than age 65 y and one
in seven will be > 75 y of age [2]. Consequently, demand for
health and long-term care, as well as expenses for pensions and
social security, will increase signiﬁcantly. More importantly,
health expectancy is 8 to 11 y shorter than life expectancy, that
is, the last decade of life is marked by disability and disease [1],
to which the loss of cognitive functions and the increase in
dementia is an important contributor. Dementia is not a diseaset to the manuscript. MHM
ted to writing the manu-
Products, but no conﬂicts
the content of this paper.
: þ41 61 815 8840.
Mohajeri).
Inc. This is an open access articlwith a given etiology, but it is rather a group of chronic symp-
toms that are common to different neurologic disorders. These
symptoms can include disorientation and impaired memory,
language and reasoning competencies. Moreover, demented
individuals progressively lose the capability to care for them-
selves accompanied by a deterioration of nutritional status [3].
Here we combine intake data and physiological data for
proper brain functioning, as well as results from epidemiology
studies and randomized placebo-controlled trials to examine the
importance of micronutrients and polyunsaturated fatty acids
(PUFAs) during brain aging and for maintaining neuronal health
and proper cognitive performance. An attempt is made to deﬁne
the role of nutrition in the development and progression of
Alzheimer’s disease (AD), which appears to be of particular in-
terest as there is so far no curative treatment established for
these patients. We will primarily concentrate on late-onset,
sporadic AD, as it is the most common form and is thought to
have a weaker genetic component [4]. Therefore, a greater po-
tential for the effects of environmental factors, such as nutrition,
may be anticipated.e under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/
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Aging has been deﬁned as the collection of changes that
render human beings progressivelymore likely to die [5]. Indeed,
one of its hallmarks in humans is an age-related increase in
mortality rates shortly after maturity [5]. Although the aging
process itself is distinct from disease, it increases the vulnera-
bility to become inﬁrm [6,7]. It is important tomention that brain
aging is not a single process, but an accumulation of modiﬁca-
tions, affecting different parts of the brain to varying degrees [8].
Aging and its linked pathologies also are accompanied by a
multitude of social changes. Decreased income after retirement,
lack of mobility and social contacts, as well as intake of multiple
medications, chronic alcoholism, depressive mood, and loss of
appetite often lead to a decrease in food intake [9]. Due to
physical disabilities and confusion resulting from dementia,
depression, or other psychological factors, older individuals tend
to be less capable of preparingmeals for themselves [9], resulting
in decreased food intake [10]. Additionally, the mechanisms
controlling food intake and the ability to compensate normal
daily ﬂuctuations in energy intake appear to declinewith age [10,
11]. Moreover, the correlation between stomach content and
hunger declines, and meals become smaller and less frequent
[12]. This reduced effectiveness to detect and react to hunger
makes this population particularly vulnerable to malnutrition
[10]. Furthermore, appetite is reduced by weakened taste and
smell sensitivities, various pathological conditions or medica-
tions, and impaired chewing due to ill-ﬁtting dentures [13].
Decreased secretion of saliva due to age, or the intake of certain
drugs, also makes swallowing more difﬁcult [14].
In addition to age-related issues with swallowing and food
intake, the efﬁciency of the stomach often is impaired due to
decreased secretion of gastric acid, pepsin, andmucus as well as a
reduction in gastric emptying and blood supply, although this is
rarely caused by older age alone [14]. Malabsorption may be the
result of surgery or pathological conditions such as Crohn’s,
Whipple’s, or celiac diseases; alcoholism; or certain infections [15,
16]. InfectionswithHeliobacter pylori,which iswidespread inolder
people, manifests with symptoms such as anorexia, problems
swallowing, bleeding in the upper gastrointestinal tract, vomiting,
weight loss, and anemia [14]. With age, the gut microbiota shifts
toward an increase in enterobacteria at the cost of anaerobes and
biﬁdobacteria, which increases the vulnerability to diarrheal dis-
eases [17]. The susceptibility is further elevated by increased
intake of antibiotics or other drugs and a decreased immune de-
fense [18]. At the same time, constipation iswidespreaddue to lack
of exercise, dehydration, low intake of dietary ﬁbers, and drug
treatment [19]. Another commoncause for constipation is irritable
bowel syndrome, which also can cause anemia, weight loss, and
rectal bleeding [14]. These changes have been associated with
increased risk for malnutrition and inadequate supplies of
micronutrients in the older population [20] (Fig.1).
Alzheimer’s disease
AD, an age-related debilitating progressive neurologic disease,
is the leading cause of senile dementia and the fourth leading
cause of death in industrialized societies [21]. Currently, >35
million individuals are afﬂicted with AD worldwide, and these
numbers are expected toquadruple by2050 [22]. Althoughdeaths
from HIV, stroke, and heart disease decreased between 2000 and
2008 by 29%, 20% and 13%, respectively, there was a 66% increase
in deaths related directly to AD during the same period (www.alz.
org/). The number of AD patients is expected to reach 13.5millionby 2050 in the United States, resulting in >$1 trillion in patient
care costs (www.alz.org). No disease-curing drug has been
developed so far for treating AD, making it one of the most
pressing public health problems in the world today [23]. Institu-
tionalized care fordemented individuals, especiallyADpatients, is
a large challenge for health and social welfare systems. Existing
AD options of medication, aiming to extend the half-life of the
neurotransmitters acetylcholine, or modulate the N-methyl-D-
aspartate receptor activity in the brain, can, at most, temporarily
retard some of the cognitive decline associated with the disease,
but they by no means, halt or reverse its progression [24–26].
AD is clinically diagnosed by progressive memory loss
accompanied by another cognitive dysfunction, such as
information-processingor language impairment. Aﬁnaldiagnosis,
however, is only possible at biopsy, where the presence of intra-
cellular neuroﬁbrillary tangles, extra-cellular amyloid (Ab) plaque
depositions, and neuronal loss conﬁrm the AD pathology [27,28].
The etiologic events leading to their generation are not entirely
understood. Mutations in genes encoding amyloid precursor
protein, presenilin 1 and 2 (APP, PS1, and PS2) are found in familial
AD and lead to accelerated deposition of Ab in animal models [28,
29]. These ﬁndings strengthen the so-called amyloid cascade
hypothesis as a dominant theory of AD pathophysiology, and they
provide associations between the presence of toxic-soluble amy-
loid oligomers and AD. Animal data show indeed that over-
expressing human Ab peptide in brains of transgenicmicemimics
some of the pathologies observed in AD, including the deposition
of amyloid plaques. Such in vivo studies set the basis for designing
therapeutic approaches in humans. These animal models, how-
ever, do not represent the full biochemical and cellular changes
found in AD [30] and despite the preclinical evidence, attempts at
ameliorating AD pathology by removing amyloid plaques from
the patient’s brain have been unsuccessful [29–32]. The problem
for AD therapy in humans is that well before dementia manifests
itself, protein aggregates trigger a number of cellular changes
leading to irreversible neuronal injury and loss. Anti-amyloid in-
terventions proved to be disappointing in the clinic, even wors-
ening the pathology at times [33]. This clinical inefﬁciency of
anti-amyloid therapies questions the validity of the amyloid
cascade hypothesis to the extent that some investigators
openly question whether this hypothesis should be tested
further [34] and it also has been claimed that deposition of Ab in
the AD brain is a consequence rather than a cause of AD [35–38].
Several additional mechanisms were proposed as alternative or
combinatory mechanisms to explain AD pathophysiology
including hormonal inﬂuence [39], inﬂammatory pathways [40],
metabolic dysfunction [41], dysregulation of metal ion homeo-
stasis [42], oxidative stress [43,44] and tau phosphorylation
[45–48]. Although all of these mechanisms are implicated in the
disease, none of these theories completely explains AD
pathology. Therefore, it is not surprising that therapeutic strate-
gies relying on any speciﬁc mechanism have not resulted in
any pharmaceutical breakthrough for AD treatment to date.
Nutritional status of the older population
Physiological changes linked to aging lead to decreased needs
for energy intake in older adults compared with young adults
with the same height, weight, and level of activity, whereas re-
quirements for micronutrients remain high [49]. Moreover, high-
energy, low-nutrient foods constitute approximately 25% of the
total energy intake in people >50 y in the United States [50],
making it difﬁcult tomeet their needs formicronutrients. In other
segments of the older population, the situation might be even
Fig. 1. Older adults are at risk for malnutrition. Various factors may cause poor coverage with essential nutrients and possible malnutrition in this age group. PUFA, poly-
unsaturated fatty acid.
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nursing homes was found to be low [51]. The reduced energy
recommendations and intakes highlight the importance of
nutrient-dense foods for the older population [52]. Nutrient
density refers to foods that have high levels of essential nutrients
per food unit and are therefore deemed high-quality foods [53]. It
was shown that nutrient density decreased as household budget
available for food went down [54]. Given the often reduced
budgets of the older population, this adds a further difﬁculty in
achieving a balanced diet with sufﬁcient micronutrients.
Various nutrients are crucial for proper brain functioning,
especially in the elderly, and adequate intakes are essential
given the age-related changes described. To get a better un-
derstanding of the adequacy of vitamin intake in older in-
dividuals in Western countries, we analyzed data collected in
the frame of dietary surveys in the United States [55–57]. Data
were selected for all adult participants with complete and reli-
able dietary records in the age range >70 y (n ¼ 2545). The
method of data collection and analysis was described else-
where [58]. National Health and Nutrition Examination Survey
(NHANES) data from 2003 to 2008 shows that intakes of vitamin
A, C, D, E, K and folate are low in a signiﬁcant proportion of the
older population in the United States (Fig. 2A, B). In Germany,
vitamin D and folate appear to be the most critical vitamins in
people ages 65 to 80 y, followed by vitamins E and C [59]
(Table 1), in both institutionalized and community-dwelling
elderly. More than 50% of older residents in German nursing
homes consumed the majority of vitamins at levels often well
below recommendations [51]. The European Nutrition and
Health Survey also reported that average intakes of vitamin D
and folate for most countries are below the recommended
levels, whereas around 50% of the countries have average in-
takes of vitamin E and C that are below recommendations [60].
Consequently, a signiﬁcant proportion of older citizens can be
expected to be at risk for multiple micronutrient deﬁciencies.
Hospitalization, which is more likely in this age group, may add
an additional risk for inadequate nutrition as it is reported that
nutritional status is likely to worsen during a hospital stay (for a
review see [61]). One reason given for the high prevalence of
inadequate intakes even in afﬂuent societies is lack of awareness
of the problem not just in the general public, but also among
health care professionals and decision makers [62]. Althoughthe controlled environment of the hospital would allow for
improved nutrition, this opportunity has so far been neglected,
likely due to lack of awareness and differing priorities. Conse-
quently, it has repeatedly been stipulated that nutrition takes a
more prominent role in the training of physicians [63].
In the United States, the nutrient-poor diet is partially
compensatedby theuseof dietary supplements. The1999 to2000
NHANES reported that >35% of people ages 60 take micro-
nutrient supplements on a regular basis [64]. InGermany, thiswas
not the case as only around 3% of tis age group were taking sup-
plements [51]. A similar situation most likely exists with micro-
nutrients supplied by fortiﬁcation and enrichment, as it was
found that fortiﬁcation served as a signiﬁcant source for vitamins
and minerals in the United States [65], but not in Europe [66].
Vitamin B12 intake levels are reported to be mostly above the
Recommended Dietary Allowance (Table 2, Fig. 2) for older in-
dividuals in theUnitedStates.However, given the level of atrophic
gastritis found in this age group [67] and the recommendations of
doses of 1000 mg/d for people with malabsorption [68], con-
cerns about the sufﬁciency of intake or bioavailability remain.
Data collected in NHANES 1999 to 2004 found that 5% to 25% of
people ages60 had low serumvitamin B12 levels, depending on
the cutoff used [69]. In Germany, intakes are lower still; vitamin
B12 deﬁciency is therefore likely to be even more common.
The increased needs of many micronutrients, such as calcium
and vitamin D in this group are difﬁcult to meet from diet alone
[70]. The same applies to levels of vitamin E, an important anti-
oxidant in the human body as concluded by the European Food
Safety Authority (EFSA; efsa.europa.eu). Vitamin E deﬁciency has
been implicated in various chronic degenerative diseases [11]. The
risk for nutrient intakes below the Estimated Average Re-
quirements is reduced four times in older persons who regularly
used supplements one or more micronutrients [71]. In older men,
the prevalence of vitamins A and E and folate intake below the
recommendations decreased from53% to 4%, from 93% to 14%, and
from 75% to 7%, respectively, with the use of supplements [71].
Cognitively normal aged brains can exhibit characteristic markers
of AD
A healthy brain is one of the organs with the highest meta-
bolic activities, and it uses a large proportion of the total nutrient
Fig. 2. Vitamin intake in the older U.S. population. Vitamin intake in older men (n ¼ 1274) (A) and women (n ¼ 1271) (B) in the United States relative to estimated average
requirements for the age group of >70 y old [139,141,183,184]. The boxplots indicate 10th, 25th, 50th, 75th, and 90th percentiles.
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functioning neural tissue is tightly regulated and depends on
optimal intakes of vitamins, structural nutrients, and minerals.
The brain is metabolically very active, depends on glucose for
energy production, and consumes w20% of the total blood
glucose, although it only accounts for 2% to 3% of body weight in
adult humans [72]. This high demand for energy makes the brain
susceptible to any metabolic insufﬁciency caused by a shortage
of essential nutrients [73].
Neurons are postmitotic, extremely specialized, and long-
living cells. As a result, they have a limited capacity to cope
with environmental stress and accumulating age-related events
[74]. Additionally, because neurons in the brain donot regenerate,
the accumulation of damage may exceed the capacity of repair
mechanisms [75]. Also, the antioxidantmachinery is less active in
brain neurons compared with other organs [76]. Therefore, an
aging brain has altered requirements of essential nutrients
including vitamins, and this need is even more pronounced in
dementia or depression [76]. In AD, markers of oxidative stress
are elevated in the brain, indicating an increased level of oxidative
stress and/or a decreased capacity to repair nucleic acid damage
[77]. A shared factor in normal brain aging, age-related degen-
erative processes, common to a variety of neurodegenerative
disorders, appears to be a decay of mitochondrial function [78].
One likely reason for this loss of function is the age-related
accumulation of oxidative damage to mitochondrial proteins,causing structural deformation and defects in key enzyme func-
tion [79]. Defective mitochondria also lead to a shortage of the
energy supply toneurons,which in turn,maystart the pathogenic
cascades leading to age-associated neuronal loss in AD [80,81].
Older individualswith an inadequate supply ofmicronutrients
and antioxidants may be at a higher risk for alterations in brain
functioning and loss of mental and emotional abilities. Addition-
ally, some of the neuropathologic changes associated with AD
(elevated amyloid burden) and cerebrovascular disease (white
matter hyperintensities) are also observed in clinically normal
older adults [78,79,82]. Both amyloid accumulation and white
matter abnormalities among clinically normal older adults pro-
vide a possible link to AD and cerebral amyloid angiopathy [83].
Moreover, prospective longitudinal studies in cognitively
normal older adults revealed that up to 45% of nondemented
individuals would histopathologically meet the criteria for AD
[84]. In particular, the pattern of regional distribution of patho-
logic changes in nondemented controls was shown tomatch that
of AD patients. Thus, mounting evidence from pathologic studies
supports the view that AD is a continuous spectrum between
asymptomatic lesions in cognitively normal older adults and
dementia, with mild cognitive impairment (MCI) as a transition
phase. The existence of pathologic hallmarks in cognitively
normal individuals suggests that they likely represent the
earliest stages of neuropathology, too early in the course of the
disease to be clinically manifest. These data support the notion
Table 1
Proportion of the population with vitamin intakes below recommended levels in the general population and in the institutionalized older population in Germany
General [59] (65–80 y) Institutionalized [51] (>65 y) Recommendation [185]
Men (%) Women (%) Men (%) Women (%) Men Women
n 1469 1562 148 606
Vitamin A 13.2 8.9 47.3 40.3 1 mg RE/d 0.8 mg RE/d
Vitamin D 94.2 97.4 92.6 95.7 5 mg/d* 5 mg/d*
Vitamin E 46.7 47.4 82.4 85.8 12 mg TE/d 11 mg TE/d
Thiamin 20.2 40.4 57.4 82.5 1 mg/d 1 mg/d
Riboﬂavin 18.5 31.8 50.7 63 1.2 mg/d 1.2 mg/d
Niacin 0.6 2.1 13.8 28.7 13 mg/d 13 mg/d
Vitamin B6 11.3 13.9 68.2 68.2 1.4 mg/d 1.2 mg/d
Folate 89.5 90.8 98.6 97 400 mg/d 400 mg/d
Vitamin B12 9.8 26.3 48 48 3 mg/d 3 mg/d
Vitamin C 30.6 30.0 84.6 84.6 100 mg/d 100 mg/d
RE, retinol equivalent; TE, tocopherol equivalent
* The recommendations for vitamin D have since been increased to 20 mg/d [186].
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cascades impacting cognitive function [83,85]. Importantly,
age-related decline of neuronal numbers in the brain is reported
in susceptible young adults [86], showing that processes leading
to neuronal loss and the impairment of brain functions may
begin at much younger ages than generally assumed. Clinical
research shows that episodic memory, the ability to recall events
in time and place, declines with age, starting as early as 20 y (93).
This ﬁnding is in agreement with animal experiments showing
the age-related neuronal loss in the rat brain starts at the end of
adolescence (94). Therefore, the search for validated biomarker
proﬁles for early detection of beginning pathology in healthy
populations is of upmost importance. Moreover, holistic inter-
vention strategies, including sufﬁcient access to micronutrients,
may be required to mitigate early decline in memory and to
improve mental well-being.Classical pharmacologic anti-AD therapies
Enormous resources have been dedicated to developing
pharmacologic therapeutics for AD, but they have done little to
help patients to date [23]. Pharmacologic approaches for primary
or secondary prevention of AD target neurotransmission, Ab
production, aggregation or clearance, tau proteins or neuro-
trophins, or they increase brain resistance to Ab or modulate
synaptic plasticity and nerve growth [23]. Moreover, hormone
replacement therapy, nonsteroidal anti-inﬂammatory drugs,
cholinesterase inhibitors, and immunization therapy were
examined in randomized controlled trials (RCTs). All have eitherTable 2
Recommended Intakes for Men and Women in the United States for the Age
Group >70 y [139,141,183,184]
Vitamin Unit/d U.S. EAR
Men Women
Vitamin A mg RE 625 500
Vitamin D mg 10 10
Vitamin E mg TE 12 12
Thiamine mg 1.0 0.9
Riboﬂavin mg 1.1 0.9
Niacin mg 12 12
Vitamin B6 mg 1.4 1.3
Vitamin B12 mg 2.0 2.0
Folic acid mg 320 320
Vitamin C mg 75 60
Vitamin K* mg 120 90
EAR, Estimated Average Requirements; RE, retinol equivalent; TE, tocopherol
equivalent
* Average nutrient requirement.failed to causally affect the onset or progression of AD pathology
or have been associated with safety concerns prompting the
conclusion that a single target or pathogenic pathway for AD is
unlikely to be identiﬁed owing to the complexity of the disease
involving manifold interactions on several levels including
genes, proteins, organelles, cells, organs, whole organism, and
environment levels [26,87]. A comprehensive review of
completed and ongoing clinical trials is given elsewhere and
concluded that none of the AD treatments to date provide
curative protection against AD pathogenesis, even if some
short-term symptomatic relief is evident [88]. Moreover, the
study postulated that focusing on several targets implicated in
AD pathology exhibits the best chances of success [88].The effect of essential micronutrients on the metabolism of aging
brain and cognitive health
Several mechanisms are identiﬁed by which micronutrients
affect cognitive function [89,90]:
1. Some essential nutrients are implicated in the synthesis of
neurotransmitters, amino acids, biogenic amines, and ste-
roids. Speciﬁcally, the metabolism of dopamine and
noradrenaline within the central nervous system (CNS) de-
pends on vitamins B2, B6, B12, nicotinamide, folate, and
vitamin C [90].
2. Thiamine, thiamine triphosphate, vitamin E, and PUFAs are
constituents of neuronal membranes, affecting membrane-
dependent properties such as neurite outgrowth, action
potential generation, and signal transduction.
3. Pyridoxine deﬁciency leads to changes in the receptor
binding of a number of neurotransmitters, including gluta-
mate and glycine.
4. Energy production in the brain is heavily dependent on
several vitamins and minerals, such as vitamin B family
members and vitamin C, as they are essential cofactors in
glycolysis, the citric acid cycle, and the respiratory chain for
producing adenosine triphosphate from glucose [73,90].
Another pathway linkingmicronutrients to cognitive function
in the adult brain is the metabolism of homocysteine (Hcy) [91].
Hcy is an amino acid produced in the body from dietary methi-
onine and is essential for normal cellular functions. However,
high Hcy concentrations can undermine normal cellular func-
tioning. Folate and vitamins B6 and B12 are implicated in the
metabolism of Hcy. Vitamin B12 plays an important role in the
transformation of Hcy into the amino acid methionine. Vitamin
Table 3
Hcy levels in AD patients and controls
Study AD patients Healthy controls P-value
Serum levels n Serum levels n
Joosten et al. 1997 [187] mmol/L 18.3 (8.2–41)* 52 12.3 (6.8–22.1)* 49 <0.01
Clarke et al. 1998 [188] mmol/L 15.3  8.4y,z 164 13.2  4.0 108 <0.05
Fekkes et al. 1998 [189] mmol/L 19.4  9.2 14 17.9  3.5 17 NS
Leblhuber et al. 2000 [190] mmol/L 17.8  6.6 19 13.8  4.2 19 <0.04
Postiglione et al. 2001 [191] mmol/L 20.9  15.0 74 11.8  5.0 74 <0.001
Hogervorst et al. 2002 [192] mmol/L 14.7  4.9 137 12.8  3.9 277 NS
McIlroy et al. 2002 [193] mmol/L 14.7 (10.9–19.4)x 83 10.7 (8.1–13.3)x 71 <0.001
Mizrahi et al. 2003 [194] mmol/L 12.3  4.3 64 11.5  3.7 64 NS
Religa et al. 2003 [195] mmol/L 18.0  9.9 99 14.4  4.5 100 <0.0001
Gallucci et al. 2004 [196] mmol/L 21.4  10.6 137 15.5  5.2 42 <0.01
Malaguarnera et al. 2004 [197] mmol/L 22.3  4.51 22 10.7  3.00 24 <0.0001
Mizrahi et al. 2004 [198] mmol/L 20.6  8.7 75 16.4  6.5 155 <0.001
Nilsson et al. 2004 [199] mmol/L 17.9  8.4 159 14.7  4.1 51 <0.01
Quadri et al. 2004 [200] mmol/L 16.8  7.0 74 14.6  6.1 55 NS
De Silva et al. 2005 [201] mmol/L 13.3  5.3 23 8.3  2.3 21 <0.01
Da Silva et al. 2006 [202] mmol/L 18.3  7.6 42 15.3  7.5 50 <0.05
Bottiglieri et al. 2001 [203] mmol/L 12.4  11.1 48 11.7  6.2 22 <0.01
Nägga et al. 2003 [204] mmol/L 16.5  6.4 47 12.9  4.2 101 <0.05
Köseoglu et al. 2007 [205] mmol/L 14.2  2.97 51 10.3  1.28 40 <0.001
Storey et al. 2003 [206] mmol/L 14.4  2.7 50 10.6  3.2 50 <0.0001
Folin et al. 2005 [207] mmol/L 21.01  7.80 79 15.78  5.55 24 <0.05
Quadri et al. 2005 [208] mmol/L 16.9  7.3 111 14.4  6.1 79 NS
Miller et al. 2002 [209] mmol/L 10.6  2.0 32 9.3  2.2 22 NS
AD, Alzheimer’s disease; Hcy, homocysteine; NS, not signiﬁcant
* Geometric mean with 95% range.
y Mean with SD (all such values).
z Clinically diagnosed patients, for histologically conﬁrmed cases (n ¼ 76), mean Hcy increases to 16.3  7.4, P < 0.01.
x Geometric mean with interquartile range.
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absence, Hcy accumulates [90,92]. Clinical research shows that
plasma levels of Hcy are signiﬁcantly higher in cases of cognitive
impairment when compared with controls [93]. Likewise,
the severity of cognitive impairment has been associated
with increased concentrations of plasma Hcy [94]. Moreover, a
signiﬁcantly higher risk for AD was reported when both folate
and B12 levels were low, and it has been suggested that high Hcy
and low B vitamin levels predict cognitive decline in aging men
[95]. Various prospective or case–control studies report Hcy
levels in AD patients and controls, showing that they tend to be
higher in AD (Table 3).
The systematic evaluation of association and/or causal tie
between marginal vitamin deﬁciencies and cognitive function
has gained broad acceptance in the past decades. The concept of
marginal vitamin deﬁciencies (suboptimal vitamin status) was
ﬁrst proposed almost 3 decades ago [96] and in a study that
introduced the triage theory [97]. According to the triage theory,
borderline micronutrient deﬁciencies accelerate aging, cancer,
and neural decay potentially causing impairment of brain func-
tion with age.
Here, we emphasize the importance of an adequate vitamin
supply for mental health by summarizing some of the mental
disorders caused directly by insufﬁcient vitamin intake or use
(Fig. 3). Thiamine deﬁciency causes beriberi and Wernicke-
Korsakoff syndrome with symptoms varying from confusion
and depression to psychosis, coma, and memory impairment
[98]. Treatment consists of reversing the thiaminedeﬁciencywith
supplemental thiamine. Deﬁciency of niacin in the diet causes the
disease pellagra, which is characterized by diarrhea, dermatitis,
and dementia. Common psychiatric symptoms of niacin deﬁ-
ciency include irritability, poor concentration, anxiety, fatigue,
restlessness, apathy, and depression due to perturbed serotonin
synthesis [99]. Vitamin B6 deﬁciency can be detected by a char-
acteristic abnormal electroencephalogram, nerve degeneration,and peripheral neuritis [100]. Neurologic symptoms of vitamin B6
deﬁciency include confusion and neuropathy. A modest vitamin
B6 deﬁciency results in impaired tryptophan-niacin conversion
affecting neurotransmitter balance within the CNS, and may lead
to mood ﬂuctuations in depressed individuals. Additionally, pyr-
idoxal phosphate–dependent enzymes play a role in the biosyn-
thesis of ﬁve important neurotransmitters: serotonin, dopamine,
adrenaline, noradrenaline and g-aminobutyric acid [100]. A
vitamin B6 deﬁciency alone is relatively uncommon and often
occurs in association with other vitamins of the B complex,
especially folate or vitamin B12 [101]. As already mentioned,
insufﬁcient supply of B vitamins, especially of thiamine, ribo-
ﬂavin, folate, and vitamin B12 are implicated in high Hcy levels
and cognitive deﬁcits, and new data suggest that B vitamins have
a preventative role against AD pathology (see later). Vitamin B6
deﬁciency also can result in impaired transsulfuration of methi-
onine to cysteine [102] systemically affecting the antioxidant
capacity and protein structure in the body and brain.
Vitamins C and E likely play roles as antioxidants in the brain.
After the pituitary gland and leukocytes, the brain has higher
vitamin C content than any other organ. Vitamin C is essen-
tial for the synthesis of the neurotransmitters dopamine and
noradrenaline [101,102], and it modulates tyrosine metabolism
[103,104]. Furthermore, ascorbate may also act as an antioxidant
protecting neurons against oxidative stress [105], particularly
because it also is needed for recycling vitamin E to its antioxidant
form [106]. Vitamin E is important for proper neuronal func-
tioning [107] and its deﬁciency leads primarily to neurologic
dysfunction such as spinocerebellar ataxia and dysarthria [108].
As a potent antioxidant, a free radical scavenger, and a constit-
uent of neuronal membranes, vitamin E prevents the oxidation
of lipids and PUFAs [108]. It has an effect on gene expression
[109–112] and is a modulator of enzymatic activities [113]. The
only symptoms of vitamin E deﬁciency in humans, caused by
mutations in the gene for a-tocopherol transfer protein, are
Fig. 3. Use of micronutrients depends on their extent of availability. Scarcity of micronutriessssnt supply enforces a prioritization of allocation to functions ensuring survival.
When micronutrients are sufﬁciently supplied throughout life, they may help to maintain brain functions as individuals age, thus potentially preventing dementia. DHA,
docosahexaenoic acid; Hcy, homocysteine.
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ataxia. Such symptoms can be treated completely by vitamin E
supplementation therapy [114,115]. Additionally, low plasma
levels of tocopherols and tocotrienols are associated with
increased odds of MCI and AD [116,117].
Low vitamin D levels are associated with anxiety and a
decline in mood, especially in the winter months [118]. Recent
data show that supplementation of healthy individuals with
vitamin D3 for 5 d prevents mood decline [118]. Vitamin D re-
ceptors are expressed broadly in the brain [119], and several
new studies hint to the importance of vitamin D for normal
cognitive performance, especially in older populations
[119–123].
Long-chain u-3 PUFAs, such as DHA, are important building
blocks for neuronal cellmembranes and are instrumental in brain
development, neurotransmission, modulation of ion channels,
andneuroprotection [31,124]. BrainDHA levels decreasewith age,
especially among AD patients, indicating that a reduced DHA
content may contribute to deterioration in memory and other
cognitive functions [31,34]. Recent data favor a role for PUFA in
slowing cognitive decline in older individuals when treated
before clinical manifestation of dementia [31,34], but this work
also suggested that the beneﬁcial effects of PUFA supplementa-
tionmaydepend on stage of disease, other dietarymediators, and
apolipoprotein (Apo) E status [125]. In general, accumulative data
support the potential of DHA to support cognitive functions in
older populations, before the onset of AD symptoms. However,
the beneﬁts of u-3 supplementation become marginal and
debatable in individuals already diagnosed with AD.
It is known that malnutrition causes oxidative stress and
inﬂammation in aged brains, which in turn may damage neural
tissues and compromise brain functions as people age [126].Nutrition-dependent biological mechanisms associated with ag-
ing include accumulative oxidative stress [73], inﬂammatory
stress [127], Hcy metabolism [91], and advanced glycation end
products [128]. The intrinsic common feature of all these factors is
that they respond and adapt to the diet. One consequence of
inadequately supplying the brain with micronutrients is the
activation of the above mechanisms, potentially leading to path-
ologic cues such as reduced cerebral blood supply, glucose toler-
ance, or brain atrophy, which change a healthy brain to an AD
brain over several decades [129]. Thus, there is a wealth of ob-
servations andexperimental knowledge that effective functioning
of the brain depends on an adequate and constant nutrient supply
and that nutrition and in particular micronutrients are key for
cognitive performance and mental well-being.
Epidemiologic data on the role of micronutrients in cognitive
health and AD
Epidemiologic studies show that multivitamins and minerals,
consumed as fruits, vegetables, or dietary supplements are
associated with lower risk for developing cognitive deﬁcits
[130–133]. Table 4 summarizes some of the studies that
compared serum levels of micronutrients in AD patients with
controls. Although the results are mixed, they provide evidence
that some of these micronutrients play an important role in the
etiology of AD. This is apparent from the fact that, in many cases,
AD patients have signiﬁcantly lower serum levels of micro-
nutrients than those of their healthy peers. Serum levels are
merely crude snapshots of an individual’s nutritional status, and it
is likely that nutritional adequacy throughout the lifecycle or
during critical periods might be more relevant. Nonetheless,
many studies show that higher micronutrient serum levels are
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meta-analysis of seven case–control studies tested thehypothesis
that hypovitaminosis D could be associated with AD. The authors
showed that higher dietary intake of vitamin D was associated
with a lower risk for developing AD among older women [120,
134] and that AD cases have lower 25-hydroxy vitamin D con-
centrations than controls [120] (Table 4). Also, in a prospectively
followed cohort of 498 olderwomen initially not taking vitaminD
supplements, the baseline dietary intake of vitamin D was asso-
ciated with the risk for onset of AD within 7 y [122]. The highest
consumption of dietary vitaminDwas associatedwith a 4.35-fold
decrease in the risk for developing AD [122].
Dietary data collected in a longitudinal study of 5092 in-
dividuals ages 65 y who were residents of Cache County, Utah,
were retrospectively evaluated [135]. In this population, a dietary
intake of B vitamins from food and supplements appeared to be
unrelated to the incidence of dementia and AD. The authors
suggested that further studies examining associations between
dietary intakes of B vitamins, biomarkers of vitamin B status, and
cognitive end points are warranted [135]. In contrast, in a study
that followed 965 individuals ages 65 y without dementia at
baseline for 6.1 y, high folate intake was shown to be linked to
decreased risk for AD independent of other risk factors and levels
of vitamins B6 and B12 [136]. In another prospective study, 579
nondemented older volunteers from the Baltimore Longitudinal
Study of Aging were followed for 9.3 y. Fifty-seven participants
developed AD. Higher intake of folate and vitamins E and B6 were
associated individually with a decreased risk for AD after
adjusting for age, sex, education, and calorie intake [137]. These
results are consistent with data showing that symptoms of de-
ﬁciencies in vitamin E and B vitamins are neurologic [138–141].
The Baltimore study further showed that participants who had
intakes 400 mg of folates had a 55% reduction in risk for
developing AD. Because intake of 400 mg folate could only be
achieved by supplementation, these authors concluded that
many people do not get the recommended amounts of folates in
their diets [103]. These data are in agreement with another study
showing that red blood cell folate, but not serum folate, was
decreased in Australian AD patients compared with healthy
controls [142]. Following an inverted U-shape curve, high folate
levels in red blood cells were associated with worse long-term
episodic memory, total episodic memory, and global cognition.
A critical review of published literature provided solid evidence
that high Hcy plasma levels are linked to a growing number of
diseases including AD [93]. In a cohort of 1112 participants (768
controls,133MCI, and 211 AD), plasmaHcy levels were associated
with cognitive deterioration [142]. Furthermore, poor vitamin B12
status was associated with neurologic problems and other
health-related conditions, including poor cognition and AD [143].
An exhaustive review of literature showed that AD patients
exhibit generally low vitamin C levels in their plasma and that
maintaining healthy vitamin C levels can have a protective func-
tion against age-related cognitive decline and AD [144]. Plasma
levels of vitamins E and C were both lower in patients with MCI
andAD comparedwith controls [145] (Table 4). Other reports hint
to a protective role of vitamin E against AD. For example, a
Swedish-Italian study showed that, after a follow-up period of 6 y,
high plasma levels of vitamin E at baselinewere associatedwith a
reduced risk for AD in advanced age. The neuroprotective effect of
vitamin E in this study seemed to be related to the combination of
different forms, rather than to a-tocopherol alone [88]. Onemeta-
analysis demonstrated that increased vitamin E intake reduced
AD risk in the older population [146]. The results of this meta-
analysis suggested that vitamins E and C and b-carotene intakescan help lower the risk for AD, and among the three antioxidants,
vitamin E exhibits the most signiﬁcant protective effect [146].
Epidemiologic data show that cognitive scores were directly
correlated with blood levels of a-tocopherol and lycopene [147]
and that vitamin E intake, from foods or supplements, was asso-
ciated with less cognitive decline with age [148]. Additionally,
increasing vitamin E intake from foods was associated with
decreased risk for developing AD after adjustment for age, edu-
cation, sex, race, ApoE ε-4, and length of follow-up [149]. These
data are supported by ﬁndings that telomeres, a marker of bio-
logical longevity, are longer in healthy women who had higher
intakes of vitamins C and E from foods [150]. Along the same line
of evidence, vitamin E was shown to increase life expectancy in
men, depending on dietary vitamin C intake and smoking [151].
Further supportof a positive roleof vitaminE inbrain function and
maintenance is provided by the ﬁnding that cognitively normal
centenarians exhibit normal levels of plasma vitamin E and A
[152], possibly contributing to the protection of centenarians
against oxidative stress and thereby to their extreme longevity.
Existing evidence links greater dietary intake of ﬁsh and
(u-3) PUFA to better early brain development and lowered risk
for cognitive disorders in late life [124]. Cross-sectional and
prospective cohort data have demonstrated that reduced
dietary intake or low brain levels of DHA are associated with
accelerated cognitive decline or the development of incipient
dementia, including AD. In a community-dwelling cohort,
levels of a-linolenic acid, eicosapentaenoic acid, and DHA were
assessed in serum phospholipids of 280 volunteers between 35
and 54 y of age, free of major neuropsychiatric disorders, and
not taking ﬁsh oil supplements [153,154]. Only the associations
between DHA and nonverbal reasoning and working memory
persisted after additional adjustment for participant education
and vocabulary scores. Thus, among the three key PUFAs, only
DHA was associated with major aspects of cognitive perfor-
mance in healthy adults <55 y old. These ﬁndings suggest that
DHA is related to brain health throughout the life span and may
have implications for clinical trials of neuropsychiatric disor-
ders [153,154].
Randomized controlled trials examining nutrients for AD
prevention and treatment
Evidence provided by numerous studies pinpoints to a
fundamental role of vitamins in cognitive performance in older
adults: A systematic review and meta-analysis of RCT reporting
the chronic effects (1 mo) of oral multivitamin supplementa-
tion on any valid cognitive outcome was performed in 2012
[155]. The authors concluded that multivitamins enhanced im-
mediate free-recall memory in cognitively healthy adults [155].
In another study, 818 mentally healthy adults, ages 50 to 75 y,
were randomized to receive a daily tablet containing 800 mg folic
acid or placebo for 3 y: Participants taking folic acid performed
better on memory tests than the placebo-treated group and as
well as individuals who were 5 y younger. Additionally, folate-
supplemented individuals exhibited scores of information pro-
cessing that were similar to those who were 2 y younger [156].
These data were consistent with the Baltimore Longitudinal
Study of Aging, showing that intake of folates and vitamins E and
B6 lowered risk for AD [137]. It has been demonstrated that
supplementing AD patients with high doses of vitamins B6 and
B12 and folate lowers plasma Hcy concentration [157]. Most
importantly, under conditions of healthy nutrition, Hcy levels
could be reduced further by administration of high-dose sup-
plements of folic acid and vitamins B6 and B12 [158].
Table 4
Data on serum vitamin levels in AD patients and controls from Cross-sectional and case–control studies
Vitamin Study AD patients Healthy controls P-value
Serum level N Serum level n
Folate Joosten et al. 1997 [187] mg/L 3.5 (1.3–9.7)* 52 3.8 (1.8–8.2) 49 NS
Clarke et al. 1998 [188] nmol/L 17.6  10.7y,z 164 22.9  10.0 108 <0.01
Leblhuber et al. 2000 [190] ng/mL 4.4  1.5 19 6.3  4.1 19 NS
Postiglione et al. 2001 [191] ng/L 5.7  2.1 74 8.5  3.2 74 <0.001
McIlroy et al. 2002 [193] mg/L 4.5 (3.2–6.5)* 83 5.1 (3.8–7.6) 71 <0.01
Religa et al. 2003 [195] ng/mL 8.5  3.4 99 7.6  5.4 100 NS
Gallucci et al. 2004 [196] ng/mL 5.1  2.7 137 6.2  4.9 42 NS
Malaguarnera et al. 2004 [197] nmol/L 10.0  2.72 22 13.9  3.0 24 <0.001
Mizrahi et al. 2004 [198] nmol/L 4.3  3.2 75 4.8  2.6 155 NS
Nilsson et al. 2004 [199] nmol/L 297  112 159 339  151 51 NS
Quadri et al. 2004 [200] nmol/L 13.6  5.6 74 16.9  5.8 55 NS
Quadri et al. 2005 [208] nmol/L 13.1  5.9 111 16.8  5.5 79 NS
De Silva et al. 2005 [201] ng/mL 7.0  3.7 23 8.7  4.3 21 NS
Bottiglieri et al. 2001 [203] nmol/L 8.0  3.4 48 12.1  10.0 14x NS
Miller et al. 2002 [209] ng/mL 461  159 32 496  212 22 NS
Köseoglu et al. 2007 [205] ng/mL 9.45  1.94 51 12.4  1.50 40 <0.001
Renvall et al. 1989 [210] ng/mL 428  213 27 582  230 10 <0.06
Vitamin B12 Joosten et al. 1997 [187] ng/L 284 (80–999) 52 284 (119–673) 49 NS
Clarke et al. 1998 [188] pmol/L 236  112 164 253  100 108 NS
Leblhuber et al. 2000 [190] pg/mL 352.4  129.3 19 383.3  188.2 19 NS
Postiglione et al. 2001 [191] pmol/L 491  144 74 780  211 74 <0.001
McIlroy et al. 2002 [193] ng/L 4.5 (3.2–6.6) 83 5.1 (3.8–7.6) 71 NS
Religa et al. 2003 [195] pg/mL 316.7  139.5 99 413.5  241.3 100 <0.05
Gallucci et al. 2004 [196] pg/mL 375.9  228.4 137 479.7  402.8 42 NS
Malaguarnera et al. 2004 [197] pmol/L 392.1  65.32 22 438.6  61.62 24 <0.05
Mizrahi et al. 2004 [198] pmol/L 322.9  136.0 75 350.5  175.3 155 NS
Nilsson et al. 2004 [199] pmol/L 254  97 159 257  129 51 NS
Quadri et al. 2004 [200] pmol/L 281  111 74 278  99 55 NS
Quadri et al. 2005 [208] pmol/L 272  108 111 275  96 79 NS
De Silva et al. 2005 [201] pg/mL 483  134.5 23 494  139 21 NS
Bottiglieri et al. 2001 [203] pmol/L 353  20.5 48 481  22.6 14x <0.05
Nägga et al. 2003 [204] pmol/L 274  80 47 307  153 94 NS
Köseoglu et al. 2007 [205] pg/mL 280  20.9 51 389.2  28.58 40 <0.001
Miller et al. 2002 [209] pg/mL 533  281 32 452  202 22 NS
Renvall et al. 1989 [210] pg/mL 442  37 21 542  178 22 <0.05
Vitamin B6 McIlroy et al. 2002 [193] nmol/L 5.6 (4.0–8.5) 83 6.4 (4.7–10.4) 71 <0.05
Malaguarnera et al. 2004 [197] nmol/L 52.0  10.78 22 57.5  8.19 24 NS
Miller et al. 2002 [209] nmol/L 121  254 32 64  37 22 NS
Vitamin C Rinaldi et al. 2003 [145] mmol/L 25.9  8.9 63 52.4  16.5 56 <0.0001
Vitamin E Rinaldi et al. 2003 [145] mmol/L 37.7  5.8 63 50.2  10.2 56 <0.0001
Bourdel-Marchasson et al. 2001 [211] mg/L 15.1  3.5 20 18.2  3.6 23 <0.01
Managialasche et al. 2012 [116] mmol/mmol cholesterol 6.49  1.54 168 7.80  2.07 187 <0.0001
Vitamin A Rinaldi et al. 2003 [145] mmol/L 2.1  0.4 63 2.6  0.3 56 <0.001
Bourdel-Marchasson et al. 2001 [211] mg/L 0.54  0.19 20 0.71  0.24 23 <0.05
Jimenez-Jimenez et al. 1999 [212] mmol/L 1.60  0.40 38 1.89  0.53 42 <0.05
B-Carotene Rinaldi et al. 2003 [145] mmol/L 0.59  0.28 63 0.57  0.33 56 NS
Jimenez-Jimenez et al. 1999 [212] mmol/L 0.21  0.14 38 0.32  0.26 42 <0.05
Thiamine Renvall et al. 1989 [210] IU mL1 h1 4.3  1.6k 15 3.9  1.6k 33 NS
Renvall et al. 1989 [210] IU min1 g Hb1 1.5  0.5{ 14 1.8  0.4{ 28 NS
Vitamin D Sato et al. 1998 [213] ng/mL 7.1  3.9 46 21.6 3.1 140 <0.0001
Martyn et al. 1989 [214] mg/L 11.5# 27 14.3# 34 <0.05
Sato et al. 2005 [215] ng/mL 9.2  3.5 100 24.5  6.0 100 <0.0001
Evatt et al. 2008 [216] ng/mL 34.8  15.4 97 37.0  14.5 99 NS
Buell et al. 2010 [217] ng/mL 16.9  6.3 41 20.0  8.2 211 <0.01
Ferrier et al. 1990 [218] nmol/L 32  9 15 40  25 15 NS
Kipen et al. 1995 [219] nmol/L 61  33 20 90  38 40 <0.05
Vitamin K1 Sato et al. 2005 [215] ng/mL 0.12  0.11 100 0.24  0.11 100 <0.0001
u-3 Tully et al. 2003 [220] g EPA/100 g fatty acid 0.98  0.87 108 1.58  0.62 45 <0.001
g DHA/100 g fatty acid 0.56  0.41 108 1.15  0.88 45 <0.001
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Hb, hemoglobin
* Geometric mean with interquartile range (all such values).
y Mean  SD (all such values).
z Clinically diagnosed patients, for histologically conﬁrmed cases (n ¼ 76), mean serum folate decreases to 15.2  9.5 (P < 0.01) and vitamin B12 to 215  79 (<0.05).
x Elderly patients with neurologic conditions other than dementia.
k Transketolase activity measured as mmol sedokeptolose-7-phosphate produced/mL blood/h.
{ Transketolase activity measured as pentose-5-phosphate used/min/g Hb.
# Mean value.
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idant drink containing polyphenols and vitamins B and C for AD
treatment was tested in an RCT enrolling 48 mild and moderateAD patients and 52 age-matched controls [159]. Daily con-
sumption of the antioxidant and vitamin drink for a relatively
short time led to a smaller increase in Hcy levels, compared with
M. H. Mohajeri et al. / Nutrition 31 (2015) 261–275270the placebo group, not only in cognitively healthy individuals,
but also in patients with moderate AD. These data are suggestive
of the potency of such treatments to reduce AD risk in healthy
individuals and in early stages of AD.
Because hippocampal atrophy is an established indicator for
conversion from the normal aging process to developing MCI
and dementia, one group [160] studied whether vitamin B sup-
plementation, which lowers levels of total plasma Hcy, could
slow the rate of brain atrophy in individuals with MCI. High-
doses of folic acid and vitamins B6 and B12 or placebo were
given to participants with MCI ages70 y for 24mo and changes
in the rate of atrophy of the whole brain were assessed by serial
volumetric magnetic resonance imaging scans. The treatment
response was related to baseline Hcy levels and a greater rate of
atrophy was associated with lower ﬁnal cognitive test scores.
These results indicate that treatment with Hcy-lowering B vita-
mins slows brain atrophy and improves cognitive scores in older
adults with MCI. Moreover, the mean total plasma Hcy was 30%
lower in those treated with B vitamins relative to placebo. B vi-
tamins also stabilized executive function relative to placebo
during the treatment period as there were signiﬁcant beneﬁts of
B vitamin treatment among participants with baseline Hcy above
the median (11.3 mmol/L) in global cognition, episodic memory,
and semantic memory [161].
These results were conﬁrmed by another trial (N ¼ 156) that
demonstrated that B vitamin treatment reduced cerebral atrophy
in gray matter (GM) regions speciﬁcally vulnerable to AD. In the
placebo group, higher Hcy levels at baselinewere associatedwith
faster GM atrophy, which was largely prevented by B vitamin
treatment [162]. A causal Bayesian network analysis indicated the
following chain of events: B vitamins lower Hcy, which directly
leads to a decrease in GM atrophy, thereby slowing cognitive
decline. These results show that B vitamin supplementation can
slow the atrophy of speciﬁc brain regions that are a key compo-
nent of the AD process and that are associated with cognitive
decline [162]. They also indicated that B vitamins slow cognitive
and clinical decline in MCI patients, which is reﬂected by a
reduced progression of age-related brain atrophy [161].
Plasma levels of antioxidant micronutrients, including vita-
mins E and C and b-carotene, are reduced in MCI and AD in-
dividuals when compared with age-matched controls. As
oxidative damage appears early in the course of AD pathophysi-
ology, increased intake of these micronutrients may reduce risk
for AD [145]. A RCT showed that various tocopherol forms
contribute to the vitamin E protective effects against AD [163].
These data suggest lower antioxidant defenses in various
neurologic conditions (i.e., against lipid peroxidation). Most
recently, a multicenter RCT treated 613 patients with mild to
moderate AD with either 2000 IU/d of a-tocopherol (n ¼ 152),
20mg/d ofmemantine (n¼ 155), a combination of both (n¼ 154),
or placebo (n ¼ 152) [164]. The study showed that high-dose a-
tocopherol supplementation in patients with mild to moderate
AD (who were already receiving acetylcholinesterase inhibitors
as a drug therapy) resulted in slower functional decline. The a-
tocopherol–treated group exhibited a delay in clinical progres-
sion of 19% per year compared with placebo. These ﬁndings
suggest beneﬁt of (synthetic) a-tocopherol in mild to moderate
AD by slowing functional decline and decreasing caregiver
burden [164]. These are encouraging data for vitamin E because of
the signiﬁcant results obtained for the primary outcome and for
the absence of severe adverse effects. These ﬁndings also
conﬁrmed those of an earlier RCT in individuals withmoderate to
severe AD. In that particular trial, AD progression, as determined
by cognitive testing, was delayed in patients receiving 2000 IU/dofa-tocopherol both alone and in combinationwith selegiline (a
selective monoamine oxidase inhibitor) [165].
Because PUFAs are enriched in the brain and are among the
most oxygen-sensitive constituents of cells, it is conceivable that
a reduction in the level of a potent antioxidant such as vitamin E
has a strong effect on brain physiology and function.
Several clinical trials investigating the effects of (u-3) PUFA
supplementation in AD have been completed [166], and they
provide evidence for the role of (u-3) PUFAs, especially DHA, in
improving brain health and cognitive function. A multicenter
RCT was performed at 51 U.S. research sites and involved 402
patients with mild to moderate AD. Participants were randomly
assigned to algal DHA at a dose of 2 g/d or to identical placebo
supplementation for 18 mo. Cognitive scores and the rate of
brain atrophy were not changed by the treatment in this cohort
[167]. DHA, however, did increase cognitive performance in
another RCT that tested mentally healthy individuals >55 y of
age (n¼ 485) [168,169]. Supplementation of 900 mg/d algal DHA
for 24 wk led to signiﬁcantly fewer paired associative learning
errors than placebo. Signiﬁcant positive effects on verbal recog-
nition memory and signiﬁcant decreases in resting heart rate
with DHA also were observed, indicating improved learning and
episodic memory functions as well as cardiovascular beneﬁts
associated with normal aging [168]. The studies just cited
conﬁrmed previous data, obtained by smaller supplementation
studies, comparing PUFA effects on cognitive and psychiatric
symptoms in older people [170–173]. These RCTs provided evi-
dence that PUFA supplementation consistently proved beneﬁcial
to improvement of cognitive abilities in individuals with MCI,
whereas the effects on AD patients were not obvious [170,172]. In
parallel, other RCTs showed that PUFA supplements improved
depressive symptoms in individuals with MCI [173], whereas
neuropsychiatric symptoms were not affected by a similar
supplementation regimen in patients with AD [171]. It is also
noteworthy that recent data showed that (u-3) PUFA supple-
mentation in MCI patients for 6 mo may attenuate telomere
shortening occurring with age in erythrocytes [174].
Collectively, the data reveal a beneﬁcial role for prophylactic
DHA in preventing or ameliorating cognitive decline in healthy
older adult populations, although its therapeutic effect for AD
has not been demonstrated. Also, the beneﬁts of DHA and lutein
in unimpaired older women was explored in the context of a 4-
mo RCT [175] revealing that verbal ﬂuency scores improved
signiﬁcantly in the DHA, lutein, and combined treatment groups.
Measures of mental processing speed, accuracy, and mood were
not affected by supplementation [175]. Finally, the carotenoid b-
carotene was tested to support cognitive function in adults. The
Physicians’ Health Study II showed that short b-carotene sup-
plementation (50 mg, alternate days) had no effect on cognitive
performance. In contrast, among 4052 participants with a mean
treatment of 18 y, the global score and verbal memory were
signiﬁcantly higher in the treated group [176].Discussion
Epidemiologic associations, mechanistic studies, and inter-
vention trials in humans deliver mounting evidence for the
importance of micronutrients in supporting cognitive perfor-
mance. These mechanisms can be categorized into pathways
modulating energy requirements of the brain, inﬂuencing
cellular structure, integrity, and membrane properties, modi-
fying receptor activity through changes in neurotransmitter
release and signal transduction, and by altering Hcy metabolism.
M. H. Mohajeri et al. / Nutrition 31 (2015) 261–275 271AD is one of the most prevalent, severe, and disabling disor-
ders that places a heavy burden on individuals and their families.
Experiencing lack of curative effects of current pharmacologic
therapies, it was suggested that the researchmust fundamentally
rethink the way AD is treated, namely after the onset of clinical
symptoms [24–26]. It is noted that the neuronal loss might be
too advanced when the disease is clinically obvious and there-
fore a presymptomatic therapy is probably a promising way of
preventing dementia. AD is best understood as a “dynamic and
compensatory” disease that damages the brain depending
mainly on the severity of the external aggression and on the
structural reserve [76]. This model suggests that the clinical
expression of the disease may vary widely over time, depending
on individual vulnerability to the initial phases of the degener-
ative process, the severity of the AD pathologic process at the
molecular and cellular levels, and the efﬁciency and evolution
over time of compensatory brain mechanisms. Curative treat-
ments are suggested by this model to be functional only if they
are administrated long before the emergence of clinically overt
symptoms, either to counterbalance the biological compromise
that precedes the cognitive breakdown or to promote functional
compensation [177]. Regardless of its exact molecular mecha-
nisms, AD-type dementia may be viewed as a failure of these
compensatory mechanisms in the course of progressive neuro-
degeneration. Researchers agree that AD decreases the number
of synapses thereby impairing cognition leading ultimately to
dementia [178]. Thus, they advocate strongly that treatment
scenarios should not only concentrate on treating AD hallmarks,
that is, decreasing amyloid or tau brain load, but also must
preserve these natural compensatory mechanisms [76]. More
importantly, it is suggested that Ab deposition may be a conse-
quence, rather than a causative factor, in disease pathogenesis
[37,38,179], but this is still a matter of scientiﬁc debate.
Preclinical and clinical ﬁndings indicate that the beneﬁts of
micronutrients, including vitamins, on the aging brain exceed
normalizing the vitamin deﬁciencies associated with aging
conditions. As explained by triage theory [97] and substantiated
by several intervention trials, high vitamin levels in the blood
and tissue may slow cellular and chemical changes that may be
responsible for the suboptimal functioning of the aged brain,
ultimately resulting in neuronal loss and compromised cognition
(Fig. 3). A balanced diet should cover the overall micronutrient
requirements. Nonetheless, even in industrialized countries
many segments of the population do not consume sufﬁcient vi-
tamins and minerals as they do not comply with dietary rec-
ommendations [50]. Moreover, needs may be elevated due to
demanding life circumstances in which people with adequate
intake may become insufﬁciently covered. Nutritional needs are
known to be increased during periods of extensive physical ex-
ercise, growth, emotional and physiological stress, demanding
cognitive tasks, the use of oral contraceptives, pregnancy and
lactation, smoking, high alcohol consumption, prolonged ther-
apy with antibiotics, older age, and restricted dietary intake due
to disease or dieting for weight loss [89]. In such situations,
people are particularly prone to develop vitamin deﬁciencies and
require speciﬁc coverage with micronutrients including vita-
mins, minerals, and essential fatty acids.
It must be mentioned here that several factors may result in
inconsistent ﬁndings in studies of micronutrient supplementa-
tion and cognitive performance in aged and AD individuals. A
detailed assessments of the challenges in conducting human
studies to investigate effects of (micro)nutrients was published
recently [180]. An editorial article [181], however, seriously
challenged the effectiveness of multivitamins to positively affectbrain functions. As for the cognitive performance, it was cited that
Grodstein et al. found no beneﬁcial effects of multivitamins in
their cohort of healthy male physicians [181]. These authors,
however, provided the explanation that the doses consumedmay
be too lowor the populationmay be toowell nourished to beneﬁt
from multivitamin supplementation [182]. These data are
remarkable because they hint to the difﬁculties of designing and
interpreting RCTs using (micro)nutrients considering the fact that
Grodstein et al. have already published in the same cohort of
healthy physicians, the usefulness of b-carotene to improve
cognitive performance [176]. Other explanations for inconsistent
results may include the fact that as these supplements are
nutritional products, they have modest effect sizes and cannot be
expected to beneﬁt all individuals equally because the effectsmay
be modiﬁed by genetic background, lifestyle factors, and nutri-
tional habits. Obviously, the outcome of supplementation studies
also depend on the health status of the participants. Moreover,
someworkhasbeenperformedwithpoorlydeﬁned supplements,
making it likely that the dose and bioavailability of such supple-
ments were low or variable and thus unlikely to have clinical ef-
fects. Furthermore, statistically signiﬁcant effects may be masked
by various technical details, such as the types and routes of
administration of the supplements or failure to systematically
quantify and understand the pharmacokinetics and pharmaco-
dynamics of a given supplement. Finally, the choice of appropri-
ately sensitive, validated, and standardized test measures for
measuring biomarkers and behavior, sufﬁcient sample sizes for
statistical power, and the duration of supplementation are all
instrumental in establishing the effects of supplementation.
Some of the most promising data has been reported for B
vitamins, vitamin E, and DHA supporting brain functions and
improving memory for healthy older adults experiencing de-
clines in cognitive function that occur naturally with age. Such
decline is known to precede AD. Acknowledging these beneﬁts,
the EFSA approved health claims for these micronutrients such
as “contributes to normal mental performance,” “contributes to
normal psychological functions,” “contributes to normal homo-
cysteine metabolism,” and “contributes to the maintenance of
normal brain function” to mention a few (efsa.europa.eu).
Conclusion
AD-type brain alterations increase with age in individuals
without dementia. AD-like marker patterns are reported in ce-
rebrospinal ﬂuid of about one-third of cognitively unaffected
older adults [4] or in their brains [78,79,82]. New therapeutics
were put to the test in the last decade that target the production
or accelerated removal of Ab from AD brains with the hope
to directly interfere with AD pathophysiology. Unfortunately,
these therapeutic strategies delivered mixed results accompa-
nied by lack of efﬁcacy and severe side effects (53). In summary,
continued and progressive cognitive decline in AD patients is
inevitable with current therapies.
We summarized here the data showing that a large portion of
the general population is inadequately supplied with various vi-
tamins, even in industrialized countries. Notably, aged pop-
ulations, especially those living in institutionalized settings, are at
higher risk for receiving insufﬁcient levels of essential micro-
nutrients. Moreover, several vitamins and DHA are necessary for
proper brain functioning, and their deﬁciencies negatively inﬂu-
ence cognitive performance. Epidemiologic studies show that
such insufﬁciencies are associated with age-related cognitive
decline, the prodromal stage of AD, and to AD. Therefore, some
experts argue that it is important to diagnose AD as early as
M. H. Mohajeri et al. / Nutrition 31 (2015) 261–275272possible [166–168] to enable disease treatment before full-blown
pathology affects the brain. Such efforts would open the possi-
bility of prophylactic (nutritional) anddrug therapies for AD [169].
In recent years we have witnessed many well-designed RCTs
providing evidence that different dietary compounds could help
to reduce risks for MCI and AD and to promote the maintenance
of cognitive performance. Therefore, essential nutrients may
have great potential in delaying the onset of AD if individuals
have a lifelong optimal supply. The lack of an established therapy
against AD, whose incidence is anticipated to increase further
and rapidly in an aging society, and the established roles of a
whole host of (micro)nutrients draw our attention toward opti-
mizing the nutritional status of not only older adults but also the
general population. Such efforts will sharpen our knowledge of
preventive strategies and provide additional support to estab-
lished therapeutic concepts as they become available.
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